Almac expanding personalized cancer vaccine production facilities

By Melissa Fassbender contact

- Last updated on GMT

(Image: Getty/CIPhotos)
(Image: Getty/CIPhotos)

Related tags: Cancer vaccine, Almac, Personalized medicine

The Almac Group is doubling its Edinburgh-based footprint to help meet the growing demand for personalized cancer vaccines production.

The contract development and manufacturing organization (CDMO) is doubling the footprint of its Fleming Building in the science and business park Edinburgh Technopole.

The expanded facility – which will double in size to more than 15,000 square feet – will aid the company’s scale-up of personalized cancer vaccine activities.

The CDMO ​also is investing in new laboratories and office space to meet demand.

Alastair Hay, peptides account manager at Almac Sciences said, “Personalized cancer vaccines based on neo-antigenic peptides is an exciting new era for oncology, and our Technopole site already has the world’s first GMP-certified facility specifically for the production of these peptide vaccines for clinical trials.”

Almac is not providing any further comment at this time.

Nearly a quarter of the company’s current resources in Edinburgh are engaged in cancer vaccine production, Hay said. The new space will be dedicated to this area, providing a four-fold increase in the GMP manufacturing footprint.

Almac in August 2018 announced​ that it would begin offering GMP supply of neoantigen-derived peptides for use in individualized cancer vaccine production at its Scotland-based facility.

Hay told us at the time that the company decided to launch the service following “requests from numerous parties over the last few years regarding requirement for high throughput peptide manufacture for use in individualized cancer vaccines.”

Related news

Show more

Related products

show more

Flexibility and capability in pre-filled syringes

Flexibility and capability in pre-filled syringes

Curia | 15-Nov-2021 | Technical / White Paper

Pre-filled syringes have risen in popularity in recent years but the pandemic’s impact on drug development, manufacturing and patient care has created...

What to consider when working with CRFs

What to consider when working with CRFs

Formedix | 01-Nov-2021 | Technical / White Paper

For a study to be successful, data collected must be correct and complete. To be correct and complete, forms must be well planned with meticulous attention...

Automating clinical trials for success

Automating clinical trials for success

Formedix | 06-Oct-2021 | Technical / White Paper

This article gives gives a brief overview of why automation is absolutely essential for clinical trial success.

Related suppliers

Follow us

Products

View more

Webinars